🚀 VC round data is live in beta, check it out!
Sunmax Biotechnology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sunmax Biotechnology and similar public comparables like Betterware de Mexico, Alkaloid, MedicalSystem Technology, Bioventus and more.
Sunmax Biotechnology Overview
About Sunmax Biotechnology
Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.
Founded
2001
HQ
Employees
109
Website
Financials (FY)
EV
$662M
Sunmax Biotechnology Financials
Sunmax Biotechnology reported last fiscal year revenue of $65M and EBITDA of $36M.
In the same fiscal year, Sunmax Biotechnology generated $51M in gross profit, $36M in EBITDA, and $23M in net income.
Sunmax Biotechnology P&L
In the most recent fiscal year, Sunmax Biotechnology reported revenue of $65M and EBITDA of $36M.
Sunmax Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $65M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $51M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 78% | XXX | XXX | XXX |
| EBITDA | — | XXX | $36M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 55% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 49% | XXX | XXX | XXX |
| Net Profit | — | XXX | $23M | XXX | XXX | XXX |
| Net Margin | — | XXX | 36% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sunmax Biotechnology Stock Performance
Sunmax Biotechnology has current market cap of $689M, and enterprise value of $662M.
Market Cap Evolution
Sunmax Biotechnology's stock price is $12.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $662M | $689M | 0.5% | XXX | XXX | XXX | $0.42 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSunmax Biotechnology Valuation Multiples
Sunmax Biotechnology trades at 10.3x EV/Revenue multiple, and 18.5x EV/EBITDA.
Sunmax Biotechnology Financial Valuation Multiples
As of April 19, 2026, Sunmax Biotechnology has market cap of $689M and EV of $662M.
Equity research analysts estimate Sunmax Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sunmax Biotechnology has a P/E ratio of 29.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $689M | XXX | $689M | XXX | XXX | XXX |
| EV (current) | $662M | XXX | $662M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 18.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 20.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 13.1x | XXX | XXX | XXX |
| P/E | — | XXX | 29.8x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 27.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sunmax Biotechnology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sunmax Biotechnology Margins & Growth Rates
Sunmax Biotechnology's revenue in the last fiscal year grew by 113%.
Sunmax Biotechnology's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.2M for the same period.
Sunmax Biotechnology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 113% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 55% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 23% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sunmax Biotechnology Public Comps
See public comps and valuation multiples for other Health & Beauty and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sunmax Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Betterware de Mexico | XXX | XXX | XXX | XXX | XXX | XXX |
| Alkaloid | XXX | XXX | XXX | XXX | XXX | XXX |
| MedicalSystem Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioventus | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Tau Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sunmax Biotechnology M&A Activity
Sunmax Biotechnology acquired XXX companies to date.
Last acquisition by Sunmax Biotechnology was on XXXXXXXX, XXXXX. Sunmax Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sunmax Biotechnology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSunmax Biotechnology Investment Activity
Sunmax Biotechnology invested in XXX companies to date.
Sunmax Biotechnology made its latest investment on XXXXXXXX, XXXXX. Sunmax Biotechnology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sunmax Biotechnology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sunmax Biotechnology
| When was Sunmax Biotechnology founded? | Sunmax Biotechnology was founded in 2001. |
| Where is Sunmax Biotechnology headquartered? | Sunmax Biotechnology is headquartered in Taiwan. |
| How many employees does Sunmax Biotechnology have? | As of today, Sunmax Biotechnology has over 109 employees. |
| Is Sunmax Biotechnology publicly listed? | Yes, Sunmax Biotechnology is a public company listed on Taipei Exchange. |
| What is the stock symbol of Sunmax Biotechnology? | Sunmax Biotechnology trades under 4728 ticker. |
| When did Sunmax Biotechnology go public? | Sunmax Biotechnology went public in 2012. |
| Who are competitors of Sunmax Biotechnology? | Sunmax Biotechnology main competitors are Betterware de Mexico, Alkaloid, MedicalSystem Technology, Bioventus. |
| What is the current market cap of Sunmax Biotechnology? | Sunmax Biotechnology's current market cap is $689M. |
| What is the current revenue of Sunmax Biotechnology? | Sunmax Biotechnology's last fiscal year revenue is $65M. |
| What is the current EV/Revenue multiple of Sunmax Biotechnology? | Current revenue multiple of Sunmax Biotechnology is 10.3x. |
| Is Sunmax Biotechnology profitable? | No, Sunmax Biotechnology is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.